<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808299</url>
  </required_header>
  <id_info>
    <org_study_id>StatinsHBV-1</org_study_id>
    <nct_id>NCT02808299</nct_id>
  </id_info>
  <brief_title>Liver Injury by Statins in Patients With History of Hepatitis B Virus Infection</brief_title>
  <acronym>LISHBV</acronym>
  <official_title>Liver Injury by Statins in Coronary Heart Disease (CHD) Patients With History of Hepatitis B Virus (HBV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the incidence of liver injury by statins in
      coronary heart disease (CHD) patients with history of hepatitis B virus (HBV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>changes of alanine transaminase (ALT, U/L)</measure>
    <time_frame>one month, three months, six months</time_frame>
    <description>The peak increases of ALT from baseline to follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of participants with alanine transaminase (ALT) increasing over 3 folds of upper limit normally (ULN)</measure>
    <time_frame>one month, three months, six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of participants with alanine transaminase (ALT) increasing over the ULN</measure>
    <time_frame>one month, three months, six months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Liver Injury</condition>
  <condition>Hepatitis B Virus Infection History</condition>
  <arm_group>
    <arm_group_label>all the antigen and antibody of HBV are negative</arm_group_label>
    <description>Hepatitis B Virus surface antigen (HBsAg), Hepatitis B Virus surface antibody (HBsAb), Hepatitis B Virus e antigen (HBeAg), Hepatitis B Virus e antibody (HBeAb), Hepatitis B Virus core antibody (HBcAb) are all negative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBV infection history</arm_group_label>
    <description>One or more of HBsAb,HBeAb, HBcAb are positive, while HBsAg and HBeAg are negative. If only HBsAb is positive, the history of HBV vaccination need to be excluded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBV carriers</arm_group_label>
    <description>One or two of HBsAg and HBeAg are positive, accompanied by any HBV antibody is positive or not.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HBV infection history</intervention_name>
    <description>HBV infection history or HBV carriers</description>
    <arm_group_label>HBV infection history</arm_group_label>
    <arm_group_label>HBV carriers</arm_group_label>
    <other_name>HBV carriers</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosied as coronary heart disease (CHD) at hospitalization receive long-term
        statin treatment, with or without HBV infection history.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with CHD receive long-term statin treatment

        Exclusion Criteria:

          -  ALT is over ULN at baseline

          -  infection of Hepatitis A Virus, Hepatitis C Virus or Hepatitis E Virus

          -  triglyceride is over 4.5 mmol/L

          -  decompensated liver cirrhosis (Child B or C)

          -  active stage of HBV

          -  infection of Burkitt's lymphoma virus or cytomegalovirus, or other acute infectious
             disease

          -  congestive heart failure

          -  malignant tumor

          -  autoimmune disease

          -  receive other potential hepatotoxicity drugs such as immunosuppressant,
             antituberculotic and non-steroid anti-inflammatory drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhijian Yang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhijian Yang, Doctor</last_name>
    <phone>+83 13809030208</phone>
    <email>zhijianyangnj@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haoyu Meng, Master</last_name>
    <phone>+86 15805167259</phone>
    <email>15805167259@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.internationaljournalofcardiology.com/article/S0167-5273(10)00935-6/abstract</url>
    <description>Click here for more information about this study</description>
  </link>
  <link>
    <url>http://circ.ahajournals.org/content/109/23_suppl_1/III-50.long</url>
    <description>Click here for more information about this study</description>
  </link>
  <link>
    <url>http://www.journal-of-hepatology.eu/article/S0168-8278(07)00129-8/abstract</url>
    <description>Click here for more information about this study</description>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1592/phco.27.6.845/abstract;jsessionid=D7FEEA8665D404AD4218069CD7F718D2.f01t01</url>
    <description>Click here for more information about this study</description>
  </link>
  <link>
    <url>http://www.ajconline.org/article/S0002-9149(05)02147-8/abstract</url>
    <description>Click here for more information about this study</description>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1002/hep.21095/abstract</url>
    <description>Click here for more information about this study</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794385/</url>
    <description>Click here for more information about this study</description>
  </link>
  <reference>
    <citation>Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004 Jun 15;109(23 Suppl 1):III50-7. Review.</citation>
    <PMID>15198967</PMID>
  </reference>
  <reference>
    <citation>Ekstedt M, Franz√©n LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol. 2007 Jul;47(1):135-41. Epub 2007 Mar 8.</citation>
    <PMID>17400325</PMID>
  </reference>
  <reference>
    <citation>Segarra-Newnham M, Parra D, Martin-Cooper EM. Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus. Pharmacotherapy. 2007 Jun;27(6):845-51.</citation>
    <PMID>17542767</PMID>
  </reference>
  <reference>
    <citation>Balmer ML, Dufour JF. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med Wkly. 2008 Jul 26;138(29-30):415-9. doi: 2008/29/smw-12311. Review.</citation>
    <PMID>18654866</PMID>
  </reference>
  <reference>
    <citation>Cohen DE, Anania FA, Chalasani N; National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol. 2006 Apr 17;97(8A):77C-81C. Epub 2006 Feb 3.</citation>
    <PMID>16581333</PMID>
  </reference>
  <reference>
    <citation>Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology. 2006 Mar;43(3):618-31.</citation>
    <PMID>16496329</PMID>
  </reference>
  <reference>
    <citation>Lu J, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, Wu J, Zhang F, Zhang Y, Wang Y, Bi S. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One. 2009 Dec 24;4(12):e8467. doi: 10.1371/journal.pone.0008467.</citation>
    <PMID>20041146</PMID>
  </reference>
  <results_reference>
    <citation>Zhang Q, Yang Z. Can statins be used safely in coronary heart disease patients of hepatitis B virus carriers? Int J Cardiol. 2011 Jan 21;146(2):291. doi: 10.1016/j.ijcard.2010.10.087. Epub 2010 Dec 3.</citation>
    <PMID>21129795</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>June 17, 2016</last_update_submitted>
  <last_update_submitted_qc>June 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>statin</keyword>
  <keyword>hepatitis B virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Encephalitis, Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

